Claims for Patent: 9,050,263

Summary for Patent: 9,050,263

Title:	Pharmaceutical compositions for the treatment of Helicobacter pylori
Abstract:	Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
Inventor(s):	Fathi; Reza (HoHoKus, NJ), Raday; Gilead (Palo Alto, CA), Goldberg; Guy (Tel Aviv, IL), Gosselin; Patrick (Laval, CA)
Assignee:	RedHill Biopharma Ltd. (Tel-Aviv, IL)
Application Number:	14/179,197
Patent Claims:	1. A capsule, comprising: (1) an immediate release first dosage composition in the form of compressed minitablets, the immediate release first dosage composition comprising at least two antibiotics; and (2) a delayed release second dosage composition in the form of compressed minitablets, the delayed release second dosage composition comprising a proton pump inhibitor and a coating, wherein, when tested in a basket apparatus, the delayed release second dosage composition meets the two stage test dissolution profile in a basket apparatus: (a) release of not more than 10% by weight of the proton pump inhibitor in 120 min in an acid stage comprising 900 ml 0.1N HCl at 100 rpm; and (b) release of not less than 75% by weight of the proton pump inhibitor in 45 min in 900 ml phosphate buffer pH 6.8 at 100 rpm following the acid. 2. The capsule of claim 1 wherein the coating in the second dosage composition delays the release of the proton pump inhibitor from 120 to at least 240 minutes following oral administration. 3. The capsule of claim 1 wherein the first dosage composition comprises amoxicillin and ansamycin, derivatives thereof, or pharmaceutically acceptable salts and or solvates thereof. 4. The capsule of claim 3 wherein the ansamycin comprises rifampicin, rifabutin, derivatives thereof, pharmaceutically acceptable salts or solvates thereof or combinations thereof. 5. The capsule of claim 1 wherein, in the second dosage composition, the proton pump inhibitor is one of omeprazole, pantoprazole, lansoprazole, ilaprazole, dexlansoprazole, esomeprazole or rabeprazole, pharmaceutically acceptable salt or solvates thereof or combinations thereof. 6. The capsule of claim 1 wherein the second dosage composition comprises a time delay agent. 7. The capsule of claim 6 wherein the time delay agent is one of sodium alginate, glyceryl monostearate, glyceryl distearate, acrylic acids, celluloses or combinations thereof. 8. The capsule of claim 1 wherein at least 70% by weight of the at least two antibiotics are released between 5 and 120 minutes following oral administration; and at least 70% by weight of the proton inhibitor is released between 120 and 240 min following oral administration. 9. The capsule of claim 1 comprising rifabutin, amoxicillin and omeprazole. 10. The capsule of claim 9 wherein the amoxicillin to rifabutin ratio ranges from 10 to 40 by weight. 11. The capsule of claim 9 wherein the amoxicillin to omeprazole ratio ranges from 20 to 40 by weight. 12. The capsule claim 1, the first and second dosage compositions further comprising a filler, a disintegrant, a binder, a surfactant, an alkalizing agent, a lubricant or combinations thereof. 13. The capsule of claim 12 wherein the filler is one of lactose, cellulose, starch, calcium phosphates, calcium carbonate, sugar, or combinations thereof. 14. The capsule of claim 12 wherein the disintegrant is one of croscarmellose sodium, carboxymethyl cellulose, sodium starch glycolate, crospovidone or combinations thereof. 15. The capsule of claim 12 wherein the binder is one of starch, cellulose, polyvinylpyrrolidone, xanthan gum, alginic acid, agar or combinations thereof. 16. The capsule of claim 12 wherein the surfactant is one of sodium lauryl sulphate, polyoxyethylene polyoxypropylene glycol, polyethylene glycol, poplypropylene glycol, polyvinyl caprolactam--polyvinyl acetate--polyethylene glycol, macrogolglycerol hydroxystearate or combinations thereof. 17. The capsule of claim 12 wherein the alkalizing agent is one of meglumine, calcium carbonate, sodium sulfate, sodium bicarbonate or combinations thereof. 18. The capsule of claim 12 wherein the lubricant is one of magnesium stearate, silicon dioxide, talc, stearic acid, sodium stearyl fumarate, glyceryl behenate or combinations thereof. 19. The capsule of claim 1 wherein the first dosage composition comprises 250 mg amoxicillin and 12.5 mg rifabutin, derivatives thereof, or pharmaceutically acceptable salts or solvates thereof and wherein the second dosage composition comprises 10 mg omeprazole, derivatives thereof, or pharmaceutically acceptable salts or solvates thereof. 20. The capsule of claim 1, wherein the second dosage composition comprises an outer protective layer, an enteric coating and an inner protective layer. 21. A method for treating H. pylori in a host comprising administering to a host the capsule of claim 1 three times a day. 22. The method of claim 21 comprising treating a host for at least 14 days and wherein the treatment results in an eradication rate greater than 84%. 23. The method of claim 21 wherein 3000 mg amoxicillin, 120 mg omeprazole and 150 mg rifabutin is administered daily. 24. The method of claim 21 wherein up to 4500 mg amoxicillin and up to 300 mg rifabutin is administered daily.